Abstract
Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.
Original language | English |
---|---|
Pages (from-to) | 1439-1440 |
Number of pages | 2 |
Journal | Cancer Treatment Reports |
Volume | 70 |
Issue number | 12 |
Publication status | Published - 1986 |
ASJC Scopus subject areas
- Cancer Research
- Oncology